关键信息
-
基因名
DES1-3 IGF-I/IGF-1
- 应用
-
别名
rHuIGF-1; IGF-IA; Somatamedin C; MGF; IGF-I
-
种属
Human
-
表达系统
E. coli
-
标签
Tag Free
-
纯度
Greater than 95% as determined by reducing SDS-PAGE.
-
蛋白编号
P05019-1
-
表达区间
T52-A118
-
蛋白长度
Full Length of Isoform-1 Mature Protein
-
分子量
9 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
DES1-3 IGF-I/IGF-1 recombinant proteins are an important area of research due to their significant role in growth and development in mammals. Insulin-like Growth Factor I (IGF-I) is a key mediator of growth hormone action and is crucial for cellular proliferation and differentiation. The recombinant form of IGF-I, specifically DES1-3 IGF-I, has been engineered to enhance its biological potency and specificity. This modified variant exhibits improved affinity for IGF receptors, leading to more pronounced physiological effects. Research has shown that DES1-3 IGF-I plays a critical role in various biological processes, including muscle growth, bone density enhancement, and metabolic regulation. Moreover, the therapeutic potential of IGF-I recombinant proteins extends to treating growth disorders, degenerative diseases, and even age-related conditions. The unique properties of DES1-3 IGF-I render it a promising candidate for various clinical applications, prompting ongoing studies to elucidate its mechanisms of action, optimize its therapeutic efficacy, and evaluate its safety profile. Understanding the implications of this recombinant protein could pave the way for novel therapeutic strategies to enhance health outcomes across different age groups.
